3K3A-APC

Drug Profile

3K3A-APC

Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-Biotech; Human-recombinant-3K3A-APC; Recombinant variant of human activated protein C (3K3A-APC)-ZZ-Biotech

Latest Information Update: 30 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Socratech; The Scripps Research Institute; University of Southern California
  • Developer The Scripps Research Institute; University of Southern California; University of Sydney; ZZ Biotech
  • Class Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Preclinical Amyotrophic lateral sclerosis; Diabetic foot ulcer; Neurological disorders; Septic shock

Most Recent Events

  • 29 Jan 2018 Preliminary efficacy and adverse events data from a phase II RHAPSODY trial in Stroke released by ZZ Biotech
  • 09 Jan 2018 ZZ Biotech completes a phase II trial in Stroke in USA (IV) (NCT02222714)
  • 10 Jul 2017 Preclinical trials in Diabetic foot ulcer in USA (IV) before July 2017 (ZZ Biotech pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top